WO2010094996A1 - Composición farmacéutica oral para uso en enfermedades respiratorias - Google Patents
Composición farmacéutica oral para uso en enfermedades respiratorias Download PDFInfo
- Publication number
- WO2010094996A1 WO2010094996A1 PCT/IB2009/007023 IB2009007023W WO2010094996A1 WO 2010094996 A1 WO2010094996 A1 WO 2010094996A1 IB 2009007023 W IB2009007023 W IB 2009007023W WO 2010094996 A1 WO2010094996 A1 WO 2010094996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenylephrine
- loratadine
- formulation
- film
- release
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract description 5
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 48
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 48
- 229960003088 loratadine Drugs 0.000 claims abstract description 35
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000004005 microsphere Substances 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 239000002998 adhesive polymer Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 6
- 238000013265 extended release Methods 0.000 claims description 5
- 230000000979 retarding effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 2
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 2
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 84
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 15
- 239000000739 antihistaminic agent Substances 0.000 abstract description 12
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract description 11
- 230000001387 anti-histamine Effects 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000000133 nasal decongestant Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 description 53
- 239000011230 binding agent Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 229920001688 coating polymer Polymers 0.000 description 5
- 239000000850 decongestant Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 loratadine Chemical compound 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229920003141 Eudragit® S 100 Polymers 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940080781 loratadine 5 mg Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940071341 phenylephrine 20 mg Drugs 0.000 description 1
- 229940032553 phenylephrine 30 mg Drugs 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to an oral pharmaceutical composition in hard gelatin capsules with coated cores containing loratadine and phenylephrine.
- This design provides the characteristic of being an immediate and modified release formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/202,743 US20120064155A1 (en) | 2009-02-20 | 2009-10-01 | Oral pharmaceutical composition for use in respiratory diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2009/001925 | 2009-02-20 | ||
MX2009001925A MX2009001925A (es) | 2009-02-20 | 2009-02-20 | Composicion farmaceutica oral para uso en enfermedades respiratorias. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010094996A1 true WO2010094996A1 (es) | 2010-08-26 |
Family
ID=42633450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/007023 WO2010094996A1 (es) | 2009-02-20 | 2009-10-01 | Composición farmacéutica oral para uso en enfermedades respiratorias |
Country Status (9)
Country | Link |
---|---|
US (1) | US20120064155A1 (es) |
AR (1) | AR075058A1 (es) |
CO (1) | CO6410284A2 (es) |
CR (1) | CR20110436A (es) |
DO (1) | DOP2011000267A (es) |
HN (1) | HN2011002258A (es) |
MX (1) | MX2009001925A (es) |
PE (1) | PE20120173A1 (es) |
WO (1) | WO2010094996A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9795571B2 (en) | 2014-09-19 | 2017-10-24 | The Procter & Gamble Company | Pulsed release phenylephrine dosage forms |
WO2018138652A1 (es) * | 2017-01-26 | 2018-08-02 | Laboratorios Liomont, S.A. De C.V. | Composición farmacéutica de loratadina, fenilefrina, paracetamol y amantadina para su administracion oral, para el tratamiento de alopatías relacionadas a un resfriado comun |
US10278930B2 (en) | 2017-03-16 | 2019-05-07 | The Procter & Gamble Company | Method for relieving sinus congestion |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007143156A1 (en) * | 2006-06-01 | 2007-12-13 | Schering Corporation | Phenylphrine pulsed release formulations and pharmaceutical compositions |
WO2007143155A2 (en) * | 2006-06-01 | 2007-12-13 | Schering-Plough Healthcare Products, Inc. | Sustained release pharmaceutical dosage form containing phenylephrine |
US20080020055A1 (en) * | 2006-06-01 | 2008-01-24 | David Monteith | Phenylephrine Pharmaceutical Formulations and Compositions for Colonic Absorption |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1255968B (it) * | 1992-11-27 | 1995-11-17 | Composizioni farmaceutiche contenenti acido ursodesossicolico | |
US20050152967A1 (en) * | 2003-03-28 | 2005-07-14 | Pfab, Lp | Dynamic variable release |
-
2009
- 2009-02-20 MX MX2009001925A patent/MX2009001925A/es active IP Right Grant
- 2009-10-01 PE PE2011001495A patent/PE20120173A1/es active IP Right Grant
- 2009-10-01 WO PCT/IB2009/007023 patent/WO2010094996A1/es active Application Filing
- 2009-10-01 US US13/202,743 patent/US20120064155A1/en not_active Abandoned
-
2010
- 2010-02-17 AR ARP100100462A patent/AR075058A1/es not_active Application Discontinuation
-
2011
- 2011-08-16 CR CR20110436A patent/CR20110436A/es unknown
- 2011-08-19 DO DO2011000267A patent/DOP2011000267A/es unknown
- 2011-08-19 HN HN2011002258A patent/HN2011002258A/es unknown
- 2011-08-19 CO CO11105852A patent/CO6410284A2/es not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007143156A1 (en) * | 2006-06-01 | 2007-12-13 | Schering Corporation | Phenylphrine pulsed release formulations and pharmaceutical compositions |
WO2007143155A2 (en) * | 2006-06-01 | 2007-12-13 | Schering-Plough Healthcare Products, Inc. | Sustained release pharmaceutical dosage form containing phenylephrine |
US20080020055A1 (en) * | 2006-06-01 | 2008-01-24 | David Monteith | Phenylephrine Pharmaceutical Formulations and Compositions for Colonic Absorption |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9795571B2 (en) | 2014-09-19 | 2017-10-24 | The Procter & Gamble Company | Pulsed release phenylephrine dosage forms |
US10376478B2 (en) | 2014-09-19 | 2019-08-13 | The Procter & Gamble Company | Pulsed release phenylephrine dosage forms |
WO2018138652A1 (es) * | 2017-01-26 | 2018-08-02 | Laboratorios Liomont, S.A. De C.V. | Composición farmacéutica de loratadina, fenilefrina, paracetamol y amantadina para su administracion oral, para el tratamiento de alopatías relacionadas a un resfriado comun |
US10278930B2 (en) | 2017-03-16 | 2019-05-07 | The Procter & Gamble Company | Method for relieving sinus congestion |
US10517840B2 (en) | 2017-03-16 | 2019-12-31 | The Procter & Gamble Company | Method for relieving sinus congestion |
Also Published As
Publication number | Publication date |
---|---|
MX2009001925A (es) | 2010-08-20 |
CR20110436A (es) | 2011-10-24 |
PE20120173A1 (es) | 2012-03-24 |
CO6410284A2 (es) | 2012-03-30 |
HN2011002258A (es) | 2014-06-16 |
AR075058A1 (es) | 2011-03-09 |
DOP2011000267A (es) | 2011-12-31 |
US20120064155A1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9289390B2 (en) | Taste masked pharmaceutical composition | |
ES2667944T3 (es) | Gránulos y comprimidos orodispersables que contienen oxicodona | |
JP5845172B2 (ja) | 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物 | |
ES2199378T3 (es) | Formulacion de morfina para via oral en forma de multiparticulas. | |
AU2005307052B2 (en) | Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane | |
ES2550035T3 (es) | Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos | |
ES2303238T3 (es) | Preparacion granulada de liberacion lenta que contiene una droga con estructura de amina con base en particulas con una capa de recubrimiento y el correspondiente metodo de produccion. | |
JP7296185B2 (ja) | 重水素化ドンペリドン組成物及び疾患の治療方法 | |
TW200522981A (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
ES2885437T3 (es) | Formulación de combinación de tesofensina y metoprolol | |
ES2364538T3 (es) | Combinación farmacéutica de alisquireno y valsartán. | |
ES2616115T3 (es) | Forma farmacéutica oral de liberación controlada que comprende oxicodona | |
BRPI0621633A2 (pt) | composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada | |
WO2010094996A1 (es) | Composición farmacéutica oral para uso en enfermedades respiratorias | |
ES2402865T3 (es) | Formulación farmacéutica que contiene fluvastatina | |
ES2936832T3 (es) | Formulaciones farmacéuticas de linagliptina | |
ES2774473T3 (es) | Forma de dosificación combinada de un antagonista del receptor opioide mu y un agente opioide | |
BRPI0715756A2 (pt) | composiÇço farmacÊutica, uso da mesma e medicamento | |
US20080014261A1 (en) | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | |
ES2351067T3 (es) | Composiciones farmacéuticas fáciles de tragar, que no provocan una sensación desagradable en la boca y que comprenden partículas con un ingrediente activo. | |
ES2633106T3 (es) | Composición oral compleja que comprende pseudoefedrina y levocetirizina | |
EP3764983B1 (en) | A sustained release formulation comprising acemetacin with bimodal in vitro release | |
ES2697609T3 (es) | Composición farmacéutica que contiene un agente antimuscarínico y método para la preparación del mismo | |
ES2896150T3 (es) | Composiciones líquidas de liberación prolongada de guaifenesina | |
JP2004035535A (ja) | 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09840265 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001495-2011 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000436 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11105852 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13202743 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09840265 Country of ref document: EP Kind code of ref document: A1 |